30-Second Takeaway
- Multi-locus genetic dosage predicts marked, dose-dependent dementia risk in Parkinson’s disease.
- FH genetic testing practices lack global standardization, potentially affecting diagnostic accuracy.
Week ending May 16, 2026
Grand Rounds: Selected genetic medicine evidence briefs (May 2026)
Visual arrays and behavioral nudges did not change Lynch syndrome risk estimates or sharing intentions
In a randomized online trial (n=1041), standard versus sequential icon arrays produced similar colorectal cancer risk estimates (60.36% vs 60.91%, p=0.58). A behavioral nudge in the communication frame did not increase intention to share genetic results with relatives (p=0.23). Effects were consistent across health literacy, education, prior testing, personal and family cancer history.
Dose-dependent multi-locus genetic burden strongly increases dementia risk in Parkinson’s disease
Meta-analysis of 24 cohorts (n=7745, 28,737 visits, 15 years) found dementia risk rose monotonically with number of progression loci. One locus conferred HR 1.56, two loci HR 3.21, and ≥3 loci HR 7.49 for dementia versus no loci. Individual loci (GBA1, APOE ε4, RIMS2, TMEM108, WWOX) associated with higher risk, but cohort heterogeneity was present.
Herbal medicine use and data‑protection concerns shape pharmacogenomics attitudes in British South Asians
Survey of 553 British South Asian adults found 66% used herbal remedies, commonly Black seed, turmeric, and ginger, which inhibit CYP2C9. Fifty‑eight percent were willing to provide DNA for PGx testing but 69% feared data misuse and 87% wanted stronger data protections. Herbal use correlated with lower reported medication adherence and higher perceived inefficacy and adverse reactions versus national comparators.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.